Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - Comparison with angiotensin II receptor blockade

Life Sciences

Volumn 91, Issue 1-2, 2012, Pages 54-63

  Sasser, Jennifer M ^a   Moningka, Natasha C ^a   Tsarova, Tatsiana ^a   Baylis, Chris ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Glomerular sclerosis; Hypertension; Nitric oxide; Olmesartan; Proteinuria

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; HYDROGEN PEROXIDE; MANGANESE SUPEROXIDE DISMUTASE; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLMESARTAN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY INFARCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEINURIA; RAT; RENAL PROTECTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; ETHANOLAMINES; IMIDAZOLES; INFARCTION; KIDNEY CORTEX; KIDNEY FAILURE, CHRONIC; MALE; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES;

RATTUS;

EID: 84863987395     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.06.005     Document Type: Article

References (41)

1. S. Anderson, H.G. Rennke, and B.M. Brenner Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat J Clin Invest 77 1986 1993 2000 (Pubitemid 16062656)
2. C. Baylis Nitric oxide deficiency in chronic kidney disease. Gottschalk Lecture 2007 Am J Physiol 294 2008 F1 F9
3. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure Hypertension 42 2003 1206 1252 (Pubitemid 37553153)
4. F. de Nigris, F.P. Mancini, M.L. Balestrieri, R. Byrns, C. Fiorito, and S. Williams-Ignarro Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits Nitric Oxide 19 2008 57 63
5. C. Dessy, J. Saliez, P. Ghisdal, G. Daneau, I.I. Lobysheva, and F. Frérart Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol Circulation 112 2005 1198 1205 (Pubitemid 41216127)
6. A. Erdely, L. Wagner, V. Muller, A. Szabo, and C. Baylis Protection of Wistar-Furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase J Am Soc Nephrol 14 2003 2526 2533 (Pubitemid 37169338)
7. U. Garbin, A.F. Pasini, C. Stranieri, S. Manfro, V. Boccioletti, and L. Cominacini Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity Pharmacol Res 56 2007 515 521 (Pubitemid 350137774)
8. U. Garbin, A. Fratta Pasini, C. Stranieri, S. Manfro, C. Mozzini, and V. Boccioletti Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells Mediators Inflamm 2008 2008 367590
9. C. Gauthier, V. Leblais, L. Kobzik, J.N. Trochu, N. Khandoudi, A. Bril, J.L. Balligand, and H. Le Marec The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle J Clin Invest 102 1998 1377 1384 (Pubitemid 28467566)
10. A. Georgescu, F. Pluteanu, M.L. Flonta, E. Badila, M. Dorobantu, and D. Popov The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery Eur J Pharmacol 508 2005 159 166 (Pubitemid 40169915)
11. K.A. Griffin, M. Picken, and A.K. Bidani Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury J Am Soc Nephrol 4 1994 2023 2031 (Pubitemid 24977009)
12. S. Gschwend, M.B. Haug, M. Nierhaus, A. Schulz, R. Vetter, and P. Kossmehl Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure Life Sci 85 2009 431 437
13. J. Habibi, M.R. Hayden, J.R. Sowers, L. Pulakat, R.D. Tilmon, and C. Manrique Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats Endocrinology 152 2011 659 668
14. M.R. Hayden, J. Habibi, A. Whaley-Connell, D. Sowers, M. Johnson, and R. Tilmon Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats Am J Nephrol 31 2010 262 272
15. L.J. Ignarro Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker Blood Press Suppl 1 2004 2 16 (Pubitemid 39551565)
16. L.J. Ignarro Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol Cardiovasc Ther 26 2008 115 134 (Pubitemid 351952828)
17. A. Maffei, A. Di Pardo, R. Carangi, P. Carullo, R. Poulet, and M.T. Gentile Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation Hypertension 50 2007 652 656 (Pubitemid 47442727)
18. H. Mollnau, E. Schultz, A. Daiber, S. Balder, M. Oelze, and M. August Nebivolol prevents vascular eNOS uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells Arterioscler Thromb Vasc Biol 23 2003 615 621 (Pubitemid 36438074)
19. N.C. Moningka, J.M. Sasser, B. Croker, C. Carter, and C. Baylis Protection against age-dependent renal injury in the F344xBrown Norway male rat is associated with maintained nitric oxide synthase Mech Ageing Dev 132 2011 1 7
20. N. Moningka, T. Tsarova, J. Sasser, and C. Baylis Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade Nephrol Dial Transplant 27 2012 912 920
21. K. Norris, and C. Vaughn The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease Expert Rev Cardiovasc Ther 1 2003 51 63
22. M. Oelze, A. Daiber, R.P. Brandes, M. Hortman, P. Wenzel, and U. Hink Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II treated rats Hypertension 48 2006 677 684 (Pubitemid 44843872)
23. A. Oǧuz, M. Uzunlulu, E. Yorulmaz, Y. Yalçin, N. Hekim, and F. Fici Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus Anadolu Kardiyol Derg 7 2007 383 387 (Pubitemid 350303384)
24. A.F. Pasini, U. Garbin, C. Stranieri, V. Boccioletti, C. Mozzini, and S. Manfro Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients Am J Hypertens 21 2008 1251 1257
25. M.J. Pires, A.B. Rodríguez-Peña, M. Arévalo, B. Cenador, S. Evangelista, and A. Esteller Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction J Hypertens 25 2007 2486 2496 (Pubitemid 350060388)
26. C. Reidenbach, R.H. Schwinger, D. Steinritz, K. Kehe, H. Thiermann, and T. Klotz Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum Life Sci 80 2007 2421 2427 (Pubitemid 46830786)
27. B. Rozec, M. Erfanian, K. Laurent, J.N. Trochu, and C. Gauthier Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart J Am Coll Cardiol 53 2009 1532 1538
28. J.M. Sasser, N.C. Moningka, M.W. Cunningham Jr., B.P. Croker, and C. Baylis Asymmetric dimethylarginine in angiotensin II induced hypertension Am J Physiol 298 2010 R740 R746
29. J.M. Sasser, M. Molnar, and C. Baylis Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-l-arginine methyl ester hypertensive rats Hypertension 58 2011 197 204
30. N. Sen, Y. Tavil, H. Erdamar, H.U. Yazici, E. Cakir, and E.O. Akgül Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X Anadolu Kardiyol Derg 9 2009 371 379
31. C. Smith, M. Merchant, A. Fekete, H.L. Nyugen, P. Oh, and Y.L. Tain Splice variants of neuronal nitric oxide synthase are present in the rat kidney Nephrol Dial Transplant 24 2009 1422 1428
32. NOXV) do not predict renal vascular NO production Kidney Int 48 1995 1272 1277
33. A. Szabo, L. Wagner, A. Erdely, K. Lau, and C. Baylis Renal neuronal nitric oxide synthase protein expression as a marker of renal function Kidney Int 64 2003 1765 1771 (Pubitemid 37323705)
34. Y.-L. Tain, G. Freshour, A. Dikalova, K. Griendling, and C. Baylis Vitamin E reduces glomerulosclerosis, restores renal nNOS and suppresses oxidative stress in the 5/6 nephrectomized rat Am J Physiol 292 2007 F1404 F1410
35. Y.L. Tain, V. Muller, A.J. Szabo, A. Erdely, C. Smith, and C. Baylis Sex differences in response to rapamycin in kidney transplantation: impact on constitutive nitric oxide synthase Nitric Oxide 18 2008 80 86 (Pubitemid 350299201)
36. Y.L. Tain, S. Ghosh, R.J. Krieg, and C. Baylis Reciprocal changes of renal neuronal nitric oxide synthase-α and -β associated with renal progression in a neonatal 5/6 nephrectomized rat model Pediatr Neonatol 52 2011 66 72
37. J.E. Toblli, G. Cao, J.F. Giani, M.C. Muñoz, M. Angerosa, and F.P. Dominici Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats J Hypertens 29 2011 1613 1623
38. J. Varagic, S. Ahmad, K.B. Brosnihan, J. Habibi, R.D. Tilmon, and J.R. Sowers Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol Am J Nephrol 32 2010 557 566
39. Y. Wang, M. Zhang, Y. Liu, Y. Liu, and M. Chen The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats Vascul Pharmacol 54 2011 36 43
40. A. Whaley-Connell, J. Habibi, M. Johnson, R. Tilmon, N. Rehmer, and J. Rehmer Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat Am J Nephrol 30 2009 354 360
41. S. Xiao, A. Erdely, L. Wagner, and C. Baylis Uremic levels of BUN do not cause nitric oxide deficiency in rats with normal renal function Am J Physiol 280 2001 F996 F1000